| Year |
Citation |
Score |
| 2023 |
Chaim OM, Miki S, Prager BC, Ma J, Jeong AY, Lara J, Tran NK, Smith JM, Rich JN, Gutkind JS, Miyamoto S, Furnari FB, Brown JH. Gα12 signaling regulates transcriptional and phenotypic responses that promote glioblastoma tumor invasion. Scientific Reports. 13: 22412. PMID 38104152 DOI: 10.1038/s41598-023-49164-4 |
0.363 |
|
| 2023 |
Wang P, Zhou R, Zhou R, Feng S, Zhao L, Li W, Lin J, Rajapakse A, Lee CH, Furnari FB, Burgess AW, Gunter JH, Liu G, Ostrikov KK, Richard DJ, et al. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium. Redox Biology. 69: 102976. PMID 38052106 DOI: 10.1016/j.redox.2023.102976 |
0.389 |
|
| 2023 |
Gerritsen JS, Faraguna JS, Bonavia R, Furnari FB, White FM. Predictive data-driven modeling of C-terminal tyrosine function in the EGFR signaling network. Life Science Alliance. 6. PMID 37169593 DOI: 10.26508/lsa.202201466 |
0.334 |
|
| 2023 |
Skinner KR, Koga T, Miki S, Gruener RF, Grigore FN, Torii EH, Seelig DM, Suzuki Y, Kawauchi D, Lin B, Malicki DM, Chen CC, Benveniste EN, Patel RP, McFarland BC, ... ... Furnari FB, et al. Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars. Biorxiv : the Preprint Server For Biology. PMID 36865329 DOI: 10.1101/2023.02.24.528982 |
0.307 |
|
| 2022 |
Contadini C, Ferri A, Di Martile M, Cirotti C, Del Bufalo D, De Nicola F, Pallocca M, Fanciulli M, Sacco F, Donninelli G, Capone A, Volpe E, Keller N, Miki S, Kawauchi D, ... ... Furnari F, et al. Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy. Cell Death and Differentiation. PMID 36460775 DOI: 10.1038/s41418-022-01093-x |
0.363 |
|
| 2022 |
Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro-Oncology. PMID 36125064 DOI: 10.1093/neuonc/noac204 |
0.329 |
|
| 2022 |
Chaim OM, Miki S, Furnari F, Miyamoto S, Brown JH. Regulation of Glioblastoma Stem Cell Properties and Tumor Invasion by G Signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 35560671 DOI: 10.1096/fasebj.2022.36.S1.R5964 |
0.305 |
|
| 2021 |
Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, ... ... Furnari FB, et al. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports. 37: 109957. PMID 34731610 DOI: 10.1016/j.celrep.2021.109957 |
0.323 |
|
| 2021 |
Li J, Kaneda MM, Ma J, Li M, Shepard RM, Patel K, Koga T, Sarver A, Furnari F, Xu B, Dhawan S, Ning J, Zhu H, Wu A, You G, et al. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33846242 DOI: 10.1073/pnas.2009290118 |
0.328 |
|
| 2021 |
Oatman N, Dasgupta N, Arora P, Choi K, Gawali MV, Gupta N, Parameswaran S, Salomone J, Reisz JA, Lawler S, Furnari F, Brennan C, Wu J, Sallans L, Gudelsky G, et al. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 7. PMID 33568479 DOI: 10.1126/sciadv.abd7459 |
0.337 |
|
| 2020 |
Banisadr A, Eick M, Beri P, Parisian AD, Yeoman B, Placone JK, Engler AJ, Furnari F. EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration. Journal of Cell Science. PMID 33243756 DOI: 10.1242/jcs.247189 |
0.306 |
|
| 2020 |
He Y, Li J, Koga T, Ma J, Dhawan S, Suzuki Y, Furnari F, Prabhu VV, Allen JE, Chen CC. Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors. Neuro-Oncology. PMID 32830856 DOI: 10.1093/Neuonc/Noaa188 |
0.394 |
|
| 2020 |
Koga T, Chen CC, Furnari FB. Genome Engineering Evolves Brain Tumor Modeling. Neurologia Medico-Chirurgica. PMID 32536682 DOI: 10.2176/nmc.ra.2020-0091 |
0.304 |
|
| 2020 |
Ramakrishnan V, Xu B, Akers J, Nguyen T, Ma J, Dhawan S, Ning J, Mao Y, Hua W, Kokkoli E, Furnari F, Carter BS, Chen CC. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. Ebiomedicine. 55: 102736. PMID 32361246 DOI: 10.1016/J.Ebiom.2020.102736 |
0.302 |
|
| 2020 |
Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, ... ... Furnari FB, et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nature Communications. 11: 550. PMID 31992716 DOI: 10.1038/S41467-020-14312-1 |
0.312 |
|
| 2020 |
Wang S, Zhang Q, Tiwari SK, Lichinchi G, Yau EH, Hui H, Li W, Furnari F, Rana TM. Integrin αvβ5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy. Cell Reports. PMID 31956073 DOI: 10.1016/J.Celrep.2019.11.020 |
0.344 |
|
| 2020 |
He Y, Ma J, Dhawan S, Koga T, Furnari F, Prabhu VV, Allen JE, Chen CC. Epidermal growth factor receptor expression as a molecular determinant of glioblastoma response to the dopamine receptor D2 antagonist, ONC201. Journal of Clinical Oncology. 38: e14552-e14552. DOI: 10.1200/Jco.2020.38.15_Suppl.E14552 |
0.423 |
|
| 2020 |
Chaim OM, Ma J, Lara J, Furnari F, Myamoto S, Brown JH. Abstract A19: Regulation of glioblastoma tumor growth and stem cell properties through Gα12 and tissue factor, upstream and downstream players in YAP signaling Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-A19 |
0.505 |
|
| 2020 |
Chaim OM, Miki S, Ma J, Flores A, Miyamoto S, Furnari F, Brown JH. Regulation of glioblastoma tumor growth and stem cell properties through Gα12: an upstream player in YAP signaling The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.06682 |
0.415 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Furnari FB, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 36: 690-691. PMID 31821785 DOI: 10.1016/J.Ccell.2019.11.008 |
0.465 |
|
| 2019 |
Jameson NM, Ma J, Benitez J, Izurieta A, Han JY, Mendez R, Parisian A, Furnari F. Intron 1-Mediated Regulation of EGFR Expression In EGFR-Dependent Malignancies is Mediated by AP-1 and BET Proteins. Molecular Cancer Research : McR. PMID 31444232 DOI: 10.1158/1541-7786.Mcr-19-0747 |
0.472 |
|
| 2019 |
Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Furnari FB, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/J.Cmet.2019.06.014 |
0.535 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Furnari FB, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 35: 816. PMID 31085179 DOI: 10.1016/j.ccell.2019.04.011 |
0.465 |
|
| 2019 |
Orellana L, Thorne AH, Lema R, Gustavsson J, Parisian AD, Hospital A, Cordeiro TN, Bernadó P, Scott AM, Brun-Heath I, Lindahl E, Cavenee WK, Furnari FB, Orozco M. Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. Proceedings of the National Academy of Sciences of the United States of America. PMID 31028138 DOI: 10.1073/Pnas.1821442116 |
0.546 |
|
| 2019 |
Chowdhry S, Zanca C, Rajkumar U, Koga T, Diao Y, Raviram R, Liu F, Turner K, Yang H, Brunk E, Bi J, Furnari F, Bafna V, Ren B, Mischel PS. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature. PMID 31019297 DOI: 10.1038/S41586-019-1150-2 |
0.335 |
|
| 2019 |
Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, Koga T, Varki NM, Fenton TR, Nagahashi Marie SK, Lindahl E, ... ... Furnari FB, et al. Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. PMID 30827889 DOI: 10.1016/J.Ccell.2019.01.020 |
0.499 |
|
| 2019 |
Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, et al. Blockade of a laminin-411 - Notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment crosstalk. Cancer Research. PMID 30659021 DOI: 10.1158/0008-5472.Can-18-2725 |
0.577 |
|
| 2019 |
Benitez JA, Finlay D, Rosa-Campos A, Ma J, Koga T, Vuori K, Furnari F. Abstract LB-110: Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-110 |
0.349 |
|
| 2019 |
Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson GL, Berens ME, Furnari F, Miller CR. Abstract 331: Dynamic kinome targeting reveals kinases involved in acquired resistance to tyrosine kinase inhibitors in EGFR-driven glioblastomas Cancer Research. 79: 331-331. DOI: 10.1158/1538-7445.Am2019-331 |
0.47 |
|
| 2019 |
Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, East M, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Ryan Miller C. DRES-13. DUAL KINASE INHIBITION TO COMBAT EGFR-INHIBITOR RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 21: vi74-vi74. DOI: 10.1093/Neuonc/Noz175.300 |
0.543 |
|
| 2019 |
Koga T, Chaim I, Markmiller S, Benitez J, Parisian A, Miki S, Hessenauer F, Turner K, Venneti S, Malicki D, Wechsler-Reya R, Mischel P, Chen C, Yeo G, Furnari F. TMOD-28. AUTHENTIC HUMAN GLIOMA MODELING USING GENETICALLY ENGINEERED INDUCED PLURIPOTENT STEM CELLS Neuro-Oncology. 21: vi268-vi269. DOI: 10.1093/Neuonc/Noz175.1127 |
0.444 |
|
| 2019 |
Miki S, Koga T, Parisian A, Furnari F. TMOD-09. MODELING TERT PROMOTER MUTATION IN ISOGENIC NEXT GENERATION GBM MODELS Neuro-Oncology. 21: vi264-vi264. DOI: 10.1093/Neuonc/Noz175.1108 |
0.425 |
|
| 2018 |
Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. Regulation of protective autophagy in anoikis-resistant glioma stem cells by SDCBP/MDA-9/Syntenin. Autophagy. 1-2. PMID 30118375 DOI: 10.1080/15548627.2018.1502564 |
0.586 |
|
| 2018 |
Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, ... ... Furnari FB, et al. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell. 34: 163-177.e7. PMID 29990498 DOI: 10.1016/J.Ccell.2018.06.006 |
0.4 |
|
| 2018 |
Yu OM, Benitez JA, Plouffe SW, Ryback D, Klein A, Smith J, Greenbaum J, Delatte B, Rao A, Guan KL, Furnari FB, Chaim OM, Miyamoto S, Brown JH. YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. Oncogene. PMID 29887596 DOI: 10.1038/S41388-018-0301-5 |
0.386 |
|
| 2018 |
Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 9: 16217. PMID 29799523 DOI: 10.1038/Ncomms16217 |
0.393 |
|
| 2018 |
Talukdar S, Pradhan AK, Bhoopathi P, Shen XN, August LA, Windle JJ, Sarkar D, Furnari FB, Cavenee WK, Das SK, Emdad L, Fisher PB. MDA-9/Syntenin regulates protective autophagy in anoikis-resistant glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 29760085 DOI: 10.1073/Pnas.1721650115 |
0.556 |
|
| 2018 |
Benitez JA, Zanca C, Ma J, Cavenee WK, Furnari FB. Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts. Journal of Visualized Experiments : Jove. PMID 29757276 DOI: 10.3791/57448 |
0.521 |
|
| 2018 |
Sun L, Yu S, Xu H, Zheng Y, Lin J, Wu M, Wang J, Wang A, Lan Q, Furnari F, Cavenee W, Purow B, Li M. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. PMID 29321665 DOI: 10.1038/S41388-017-0068-0 |
0.665 |
|
| 2018 |
Jameson N, Tang J, Parisian A, Benitez J, Furnari F. GENE-38. INTRON 1-MEDIATED REGULATION OF EGFR EXPRESSION IN EGFR-DEPENDENT MALIGNANCIES Neuro-Oncology. 20: vi111-vi112. DOI: 10.1093/Neuonc/Noy148.464 |
0.442 |
|
| 2018 |
Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-08. DYNAMIC KINOME PROFILING OF GENETICALLY-DEFINED, EGFRvIII-DRIVEN MURINE ASTROCYTE MODELS OF GLIOBLASTOMA REVEALS TARGETS FOR DUAL KINASE INHIBITOR THERAPY Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.315 |
0.363 |
|
| 2018 |
Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-07. DEFINING THE MECHANISMS OF ACQUIRED RESISTANCE TO TYROSINE KINASE INHIBITORS IN EGFR-DRIVEN GLIOBLASTOMAS USING INTEGRATED KINOME AND TRANSCRIPTOME PROFILING Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.314 |
0.415 |
|
| 2018 |
Binder Z, Thorne A, Bakas S, Wileyto EP, Akbari H, Rathore S, Min Ha S, Zhang L, Idbaih A, Bagley S, Morrissette J, Nasrallah M, Ma J, Zanca C, Scott A, ... ... Furnari F, et al. CSIG-25. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION Neuro-Oncology. 20: vi48-vi48. DOI: 10.1093/Neuonc/Noy148.191 |
0.394 |
|
| 2018 |
Benitez J, Finlay D, Ma J, Koga T, Vuori K, Furnari F. CADD-21. PROTEASOME INHIBITION IS A TARGETED THERAPY FOR PTEN-DEFICIENT GLIOBLASTOMAS Neuro-Oncology. 20: vi280-vi280. DOI: 10.1093/Neuonc/Noy148.1165 |
0.31 |
|
| 2017 |
Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, ... ... Furnari FB, et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. PMID 28724615 DOI: 10.1101/Gad.300079.117 |
0.613 |
|
| 2017 |
Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, Kelly S, Khodadadi-Jamayran A, Jameson NM, Andersen M, Miletic H, Saberi S, Frazer KA, Cavenee WK, Furnari FB. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Communications. 8: 15223. PMID 28497778 DOI: 10.1038/ncomms15223 |
0.53 |
|
| 2017 |
Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, ... Furnari FB, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. PMID 28178237 DOI: 10.1038/Nature21356 |
0.462 |
|
| 2017 |
Tsuchihashi K, Okazaki S, Yoshikawa M, Seishima R, Sampetrean O, Onishi N, Wakimoto H, Furnari F, Baba E, Akashi K, Saya H, Nagano O. Abstract LB-334: xCT promotes malignant phenotypes in EGFR-expressing glioma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-334 |
0.546 |
|
| 2017 |
Koga T, Figueroa J, Carter B, Chen C, Furnari F. GENE-45. DETAILED BREAKPOINT ANALYSES IMPLY THAT EGFRvIII DELETIONS ARE GENERATED BY DIFFERENT GENOMIC REARRANGEMENTS OF AMPLIFIED FULL LENGTH EGFR Neuro-Oncology. 19: vi102-vi102. DOI: 10.1093/Neuonc/Nox168.418 |
0.342 |
|
| 2017 |
Thorne AH, Binder ZA, Bakas S, Wileyto EP, Morrissette JJD, Akbari H, Rathore S, Scott A, Davatzikos C, O’Rourke D, Furnari F. EXTH-56. EGFR EXTRACELLULAR DOMAIN POINT MUTANT A289V: A THERAPEUTICALLY TARGETABLE DRIVER OF GLIOBLASTOMA INVASION Neuro-Oncology. 19: vi85-vi85. DOI: 10.1093/Neuonc/Nox168.348 |
0.382 |
|
| 2017 |
Smithberger E, Flores A, Dhruv H, Johnson G, Berens M, Furnari F, Miller CR. EXTH-53. IMPACT OF EGFRvIII AND PTEN DELETION MUTATIONS ON RESPONSE OF Ink4a/Arf-NULL MURINE ASTROCYTES TO EGFR TYROSINE KINASE INHIBITORS Neuro-Oncology. 19: vi84-vi84. DOI: 10.1093/neuonc/nox168.345 |
0.309 |
|
| 2017 |
Koga T, Benitez J, Markmiller S, D’Antonio M, Parisian A, Saberi S, Turner K, Hessenauer M, Thorne AH, Zanca C, Mischel P, Frazer K, Yeo G, Cavenee W, Furnari F. TMOD-42. CRISPR/Cas9-EDITED HUMAN NEURAL STEM CELLS GIVE RISE TO BRAIN TUMORS RESEMBLING GLIOBLASTOMAS Neuro-Oncology. 19: vi263-vi263. DOI: 10.1093/Neuonc/Nox168.1078 |
0.546 |
|
| 2017 |
Parisian A, Koga T, Furnari F. ATRT-02. INTERACTIONS BETWEEN SMARCB1 AND CELLULAR DIFFERENTIATION STATE IN THE GENESIS OF ATYPICAL TERATOID RHABDOID TUMORS Neuro-Oncology. 19: iv1-iv1. DOI: 10.1093/Neuonc/Nox083.001 |
0.44 |
|
| 2016 |
Kegelman TP, Wu B, Das SK, Talukdar S, Beckta JM, Hu B, Emdad L, Valerie K, Sarkar D, Furnari FB, Cavenee WK, Wei J, Purves A, De SK, Pellecchia M, et al. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. Proceedings of the National Academy of Sciences of the United States of America. PMID 28011764 DOI: 10.1073/Pnas.1616100114 |
0.553 |
|
| 2016 |
Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 27825958 DOI: 10.1016/J.Jconrel.2016.11.001 |
0.653 |
|
| 2016 |
Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Furnari FB, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/J.Ccell.2016.09.008 |
0.541 |
|
| 2016 |
Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, ... ... Furnari FB, et al. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Research. PMID 26980765 DOI: 10.1158/0008-5472.CAN-15-2121 |
0.403 |
|
| 2016 |
Thorne AH, Zanca C, Furnari F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro-Oncology. PMID 26755074 DOI: 10.1093/Neuonc/Nov319 |
0.453 |
|
| 2016 |
Parisian A, Koga T, Wechsler-Reya R, Furnari F. PDTB-03. ROLE OF SMARCB1 IN PEDIATRIC RHABDOID TUMORS Neuro-Oncology. 18: vi150-vi150. DOI: 10.1093/Neuonc/Now212.623 |
0.341 |
|
| 2016 |
Zanca C, Furnari F. DRES-04. TUMOR HETEROGENEITY CONTRIBUTES TO RESISTANCE TO ANTI-EGFR THERAPY IN GLIOBLASTOMA Neuro-Oncology. 18: vi52-vi52. DOI: 10.1093/Neuonc/Now212.214 |
0.425 |
|
| 2016 |
Thorne AH, Orellana L, Parisian A, Cavenee W, Furnari F. CSIG-22. MUTATIONAL HETEROGENEITY OF THE EGFR EXTRACELLULAR DOMAIN PROMOTES AN ONCOGENIC UNTETHERED TRANSITIONAL CONFORMATION AND THE POTENTIAL FOR GREATER THERAPEUTIC TARGETING IN GBM PATIENTS Neuro-Oncology. 18: vi45-vi45. DOI: 10.1093/Neuonc/Now212.183 |
0.568 |
|
| 2016 |
Ma J, Furnari F. OS3.7 Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through enhanced DNA damage repair Neuro-Oncology. 18: iv8-iv8. DOI: 10.1093/Neuonc/Now188.025 |
0.331 |
|
| 2015 |
Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Furnari FB, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/J.Molcel.2015.09.002 |
0.59 |
|
| 2015 |
Shen Y, Li J, Nitta M, Futalan D, Steed T, Treiber JM, Taich Z, Stevens D, Wykosky J, Chen HZ, Carter BS, Becher OJ, Kennedy R, Esashi F, Sarkaria JN, ... Furnari FB, et al. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget. 6: 11751-67. PMID 26059434 DOI: 10.18632/Oncotarget.3996 |
0.586 |
|
| 2015 |
Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918 |
0.606 |
|
| 2015 |
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 160: 489-502. PMID 25619690 DOI: 10.1016/J.Cell.2015.01.001 |
0.376 |
|
| 2015 |
Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research. 75: 394-404. PMID 25432173 DOI: 10.1158/0008-5472.Can-14-2004 |
0.599 |
|
| 2015 |
Costa ET, Barnabé GF, Li M, Dias AA, Machado TR, Asprino PF, Cavalher FP, Ferreira EN, Del Mar Inda M, Nagai MH, Malnic B, Duarte ML, Leite KR, de Barros AC, Carraro DM, ... ... Furnari F, et al. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. Oncogene. 34: 1270-9. PMID 24662834 DOI: 10.1038/Onc.2014.70 |
0.602 |
|
| 2015 |
Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Ng K, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, ... ... Furnari F, et al. Abstract PR02: Dynamic epigenetic regulation of glioblastoma tumorigenicity through a LSD1-MYC-OLIG2 axis Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr02 |
0.571 |
|
| 2015 |
Zanca C, Cavenee W, Furnari F. Abstract B37: Tumor heterogeneity contributes to anti-EGFR therapy resistance in glioblastoma Brain. 75. DOI: 10.1158/1538-7445.Brain15-B37 |
0.7 |
|
| 2015 |
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller C, Furnari F, Hunter T, Brognard J, Newton AC. Abstract 125: Protein kinase C loss-of-function mutations in cancer reveal role as tumor suppressor Cancer Research. 75: 125-125. DOI: 10.1158/1538-7445.Am2015-125 |
0.458 |
|
| 2015 |
Benitez J, Boyer A, Camargo F, Zanca C, Ma J, Jameson N, Cavenee W, Furnari F. CBIO-04DAXX INHIBITION SUPPRESSES TUMOR GROWTH IN PTEN-DEFICIENT HUMAN GLIOBLASTOMAS Neuro-Oncology. 17: v55.4-v55. DOI: 10.1093/Neuonc/Nov209.04 |
0.625 |
|
| 2015 |
Thorne AH, Orellana L, Parisian A, Cavenee W, Furnari F. ATPS-86MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING Neuro-Oncology. 17: v37.3-v37. DOI: 10.1093/Neuonc/Nov204.86 |
0.628 |
|
| 2014 |
Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. PMID 25347738 DOI: 10.1038/onc.2014.336 |
0.621 |
|
| 2014 |
Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... Furnari FB, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093 |
0.589 |
|
| 2014 |
Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 5: 882-93. PMID 24658464 DOI: 10.18632/Oncotarget.1801 |
0.607 |
|
| 2014 |
Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Research. 74: 1429-39. PMID 24436148 DOI: 10.1158/0008-5472.Can-13-2117 |
0.575 |
|
| 2014 |
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Furnari FB, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328 |
0.611 |
|
| 2014 |
Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, Cheng SY. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 33: 2504-12. PMID 23728337 DOI: 10.1038/onc.2013.198 |
0.637 |
|
| 2014 |
Zanca C, Inda MdM, Bonavia R, Wykosky J, Verkhusha V, Cavenee W, Furnari F. Abstract 4933: In vivo visualization of heterogeneous cancer cell populations by fluorescence molecular tomography Cancer Research. 74: 4933-4933. DOI: 10.1158/1538-7445.Am2014-4933 |
0.681 |
|
| 2014 |
Muir S, Nathanson J, Wilbert M, Yeo G, Furnari F, Arden K, Cavenee W. Abstract 3558: The role of miRNA in PAX3-FKHR positive rhabdomyosarcoma Cancer Research. 74: 3558-3558. DOI: 10.1158/1538-7445.Am2014-3558 |
0.524 |
|
| 2014 |
Shen Y, Nitta M, Li J, Futalan D, Steed T, Taich Z, Treiber JM, Stevens D, Schroeder MA, Sarkaria JN, Chen H, Jiang T, Carter BS, Esashi F, Wakosky J, ... Furnari F, et al. Abstract 2737: Modulation of mitotic DNA damage as a paradigm for glioblastoma therapy Cancer Research. 74: 2737-2737. DOI: 10.1158/1538-7445.Am2014-2737 |
0.451 |
|
| 2014 |
Nagarajan R, Barajas R, Mazor T, Phillips J, Ma J, Hong C, Johnson B, Dayal M, Cha S, Nakamura J, Berger M, Chang S, Furnari F, Taylor B, Costello J. GE-42 * INTEGRATED RADIOGRAPHIC AND PHYLOGENETIC CASE STUDY OF A PRIMARY AND CONTRALATERAL RECURRENT GLIOMA Neuro-Oncology. 16: v105-v106. DOI: 10.1093/Neuonc/Nou256.41 |
0.436 |
|
| 2014 |
Chen C, Shen Y, Nitta M, Futalan D, Taich Z, Treiber J, Stevens D, Chen H, Carter B, Esashi F, Sarkaria J, Furnari F, Cavenee W, Desai A. DN-01 * BYPASSING GLIOBLASTOMA RESISTANCE TO EGFR INHIBITORS BY SYNTHETIC LETHALITY Neuro-Oncology. 16: v62-v62. DOI: 10.1093/Neuonc/Nou245.1 |
0.628 |
|
| 2014 |
Chen C, Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha D, Vandenberg S, Ramakrishnan V, Zhu S, Furnari F, Matsui H, Harismendy O, Cavenee W, Mao Y, et al. CB-04 * EPIGENETIC REGULATION OF GLIOBLASTOMA TUMORIGENICITY: A HYBRID MODEL Neuro-Oncology. 16: v41-v41. DOI: 10.1093/Neuonc/Nou241.4 |
0.594 |
|
| 2014 |
Furnari F, Gomez G, Volinia S, Croce C, Zanca C, Li M, Gutmann D, Brennan C, Cavenee W. MUTANT EGFR SUPPRESSION OF MICRORNA-9 INDUCES FOXP1 TO ENHANCE GLIOBLASTOMA TUMORIGENICITY Neuro-Oncology. 16: iii14-iii15. DOI: 10.1093/Neuonc/Nou206.52 |
0.549 |
|
| 2013 |
Gomez GG, Wykosky J, Zanca C, Furnari FB, Cavenee WK. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biology & Medicine. 10: 192-205. PMID 24349829 DOI: 10.7497/j.issn.2095-3941.2013.04.003 |
0.643 |
|
| 2013 |
Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Furnari FB, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527 |
0.595 |
|
| 2013 |
Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Plos Genetics. 9: e1003253. PMID 23459592 DOI: 10.1371/Journal.Pgen.1003253 |
0.598 |
|
| 2013 |
Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086 |
0.446 |
|
| 2013 |
Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110 |
0.622 |
|
| 2013 |
Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. International Journal of Cancer. Journal International Du Cancer. 132: 509-20. PMID 22729867 DOI: 10.1002/Ijc.27690 |
0.636 |
|
| 2013 |
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Furnari F, ... ... Furnari F, ... ... Furnari F, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174 |
0.522 |
|
| 2012 |
Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, ... ... Furnari FB, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/Pnas.1211962109 |
0.625 |
|
| 2012 |
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development. 26: 756-84. PMID 22508724 DOI: 10.1101/Gad.187922.112 |
0.529 |
|
| 2012 |
Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 3018-23. PMID 22323579 DOI: 10.1073/Pnas.1121457109 |
0.635 |
|
| 2012 |
Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current Cancer Drug Targets. 12: 197-209. PMID 22268382 |
0.586 |
|
| 2012 |
Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene. 31: 4054-66. PMID 22139077 DOI: 10.1038/onc.2011.563 |
0.612 |
|
| 2012 |
Wykosky J, Cavenee W, Furnari F. Abstract A27: PI3K/Akt pathway-dependent and -independent mechanisms of resistance to EGFR tyrosine kinase inhibitors in glioblastoma Clinical Cancer Research. 18: A27-A27. DOI: 10.1158/1078-0432.Mechres-A27 |
0.635 |
|
| 2012 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Chiba Y, Kinoshita M, Sugiyama H, Yoshimine T, Kim YZ, Kim KH, Lee EH, Hu B, Sim H, Mohan N, Agudelo-Garcia P, ... ... Furnari F, ... ... Furnari FB, ... ... Furnari FB, et al. LAB-CELL BIOLOGY AND SIGNALING Neuro-Oncology. 14: vi7-vi20. DOI: 10.1093/Neuonc/Nos220 |
0.522 |
|
| 2012 |
Proescholdt MA, Merrill MJ, Stoerr E, Lohmeier A, Brawanski A, Sim H, Hu B, Pineda CA, Yoon S, Viapiano MS, Rajappa P, Cobb WS, Huang Y, Lyden DC, Bromberg J, ... ... Furnari F, et al. LAB-ANGIOGENESIS AND INVASION Neuro-Oncology. 14: vi1-vi6. DOI: 10.1093/Neuonc/Nos219 |
0.535 |
|
| 2012 |
Furnari F, Fenton T, Zhou H, Marie S, Mischel P, Cavenee W. 66 Proffered Paper: PTEN Phosphorylation by Fibroblast Growth Factor Receptors and SRC Mediates Resistance to Epidermal Growth Factor Receptor Inhibitors in Glioblastoma European Journal of Cancer. 48: S16. DOI: 10.1016/S0959-8049(12)70770-0 |
0.527 |
|
| 2011 |
Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. The Journal of Experimental Medicine. 208: 2657-73. PMID 22162832 DOI: 10.1084/Jem.20111102 |
0.668 |
|
| 2011 |
Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. The Journal of Clinical Investigation. 121: 4670-84. PMID 22080864 DOI: 10.1172/Jci58559 |
0.601 |
|
| 2011 |
Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 15984-9. PMID 21896743 DOI: 10.1073/Pnas.1113416108 |
0.682 |
|
| 2011 |
Cvrljevic AN, Akhavan D, Wu M, Martinello P, Furnari FB, Johnston AJ, Guo D, Pike L, Cavenee WK, Scott AM, Mischel PS, Hoogenraad NJ, Johns TG. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. Journal of Cell Science. 124: 2938-50. PMID 21878501 DOI: 10.1242/jcs.083295 |
0.556 |
|
| 2011 |
Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, Tewari M, Furnari FB, Taniguchi T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Molecular Cancer Research : McR. 9: 1100-11. PMID 21693595 DOI: 10.1158/1541-7786.Mcr-11-0007 |
0.45 |
|
| 2011 |
Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Research. 71: 4055-60. PMID 21628493 DOI: 10.1158/0008-5472.CAN-11-0153 |
0.542 |
|
| 2011 |
Chumbalkar V, Latha K, Hwang Y, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, Bogler O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. Journal of Proteome Research. 10: 1343-52. PMID 21214269 DOI: 10.1021/Pr101075E |
0.62 |
|
| 2011 |
Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer. 30: 5-12. PMID 21192840 DOI: 10.5732/Cjc.010.10542 |
0.667 |
|
| 2011 |
Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. The Journal of Clinical Investigation. 121: 161-73. PMID 21183793 DOI: 10.1172/Jci44798 |
0.513 |
|
| 2011 |
Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D'Andrea A, Chen CC. Correction: Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy Plos One. 6. DOI: 10.1371/Annotation/9B9Cc4Ae-Ad56-464F-Ab97-59F096B5C0Eb |
0.493 |
|
| 2011 |
Li M, Cavenee W, Furnari F. Abstract 1193: Guanylate binding protein-1, a novel oncogenic gene in glioblastoma Cancer Research. 71: 1193-1193. DOI: 10.1158/1538-7445.Am2011-1193 |
0.661 |
|
| 2011 |
Inda MDM, Bonavia R, Vandenberg S, Cavenee W, Furnari F. Abstract 1129: Function of mutant EGFR in maintaining glioblastoma growth and heterogeneity Cancer Research. 71: 1129-1129. DOI: 10.1158/1538-7445.Am2011-1129 |
0.667 |
|
| 2011 |
Wykosky JE, Cavenee W, Furnari F. Abstract B73: Molecular mechanisms of glioma resistance to EGFR tyrosine kinase inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B73 |
0.645 |
|
| 2010 |
Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes & Development. 24: 1731-45. PMID 20713517 DOI: 10.1101/Gad.1890510 |
0.614 |
|
| 2010 |
Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. Plos One. 5: e10767. PMID 20532243 DOI: 10.1371/Journal.Pone.0010767 |
0.622 |
|
| 2010 |
Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee WK, Furnari FB, White FM. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular Biosystems. 6: 1227-37. PMID 20461251 DOI: 10.1039/C001196G |
0.563 |
|
| 2010 |
Wykosky J, Mukasa A, Furnari F, Cavenee WK. Escape from targeted inhibition: the dark side of kinase inhibitor therapy. Cell Cycle (Georgetown, Tex.). 9: 1661-2. PMID 20404502 DOI: 10.4161/Cc.9.9.11592 |
0.551 |
|
| 2010 |
Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America. 107: 2616-21. PMID 20133782 DOI: 10.1073/Pnas.0914356107 |
0.676 |
|
| 2010 |
Li M, Furnari F, Cavenee W. Abstract 265: EGFR positively regulates GBP1 expression to promote glioma cell invasion Cancer Research. 70: 265-265. DOI: 10.1158/1538-7445.Am10-265 |
0.671 |
|
| 2010 |
Wykosky J, Mukasa A, Chin L, Cavenee W, Furnari F. Abstract PR6: Resistance to EGFR inhibition via the emergence of EGFRvIII-independent tumor growth-promoting mechanisms in glioblastoma Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr6 |
0.684 |
|
| 2009 |
Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Furnari FB, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347 |
0.654 |
|
| 2009 |
Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B, Madden C, Maher E, Boothman DA, Furnari F, Cavenee WK, Bachoo RM, Burma S. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Research. 69: 4252-9. PMID 19435898 DOI: 10.1158/0008-5472.Can-08-4853 |
0.622 |
|
| 2009 |
Read RD, Cavenee WK, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. Plos Genetics. 5: e1000374. PMID 19214224 DOI: 10.1371/journal.pgen.1000374 |
0.622 |
|
| 2009 |
Bonavia R, Inda M, Johns T, Cavenee W, Furnari F. Abstract A181: Dissecting the crosstalk between wt and mutant EGFR in glioblastoma multiforme Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A181 |
0.681 |
|
| 2009 |
Inda M, Bonavia R, Sah DWY, Hadwiger P, Tan P, Cavenee WK, Furnari F. Abstract A180: Tumor heterogeneity in glioblastoma is actively maintained by a paracrine circuit driven by mutant EGFR Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A180 |
0.546 |
|
| 2008 |
Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 13: 355-64. PMID 18394558 DOI: 10.1016/J.Ccr.2008.02.010 |
0.525 |
|
| 2007 |
Huang PH, Cavenee WK, Furnari FB, White FM. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle (Georgetown, Tex.). 6: 2750-4. PMID 17986864 DOI: 10.4161/Cc.6.22.4922 |
0.597 |
|
| 2007 |
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & Development. 21: 2683-710. PMID 17974913 DOI: 10.1101/Gad.1596707 |
0.518 |
|
| 2007 |
Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. 104: 12867-72. PMID 17646646 DOI: 10.1073/Pnas.0705158104 |
0.594 |
|
| 2007 |
Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1911-25. PMID 17363548 DOI: 10.1158/1078-0432.Ccr-06-1453 |
0.585 |
|
| 2007 |
White F, Huang P, Cavenee W, Furnari F. 121 INVITED Network analysis of cellular signalling European Journal of Cancer Supplements. 5: 33-34. DOI: 10.1016/s1359-6349(07)70235-5 |
0.403 |
|
| 2006 |
Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5064-73. PMID 16951222 DOI: 10.1158/1078-0432.Ccr-06-0913 |
0.441 |
|
| 2006 |
Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. The Journal of Biological Chemistry. 281: 26562-8. PMID 16829519 DOI: 10.1074/Jbc.M605391200 |
0.577 |
|
| 2006 |
Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, et al. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 9: 379-90. PMID 16697958 DOI: 10.1016/J.Ccr.2006.03.028 |
0.493 |
|
| 2006 |
Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Di Vizio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, DePinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans (DOI:10.1016/j.ccr.2006.03.028) Cancer Cell. 10: 171. DOI: 10.1016/J.Ccr.2006.07.012 |
0.493 |
|
| 2005 |
Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6390-9. PMID 16144944 DOI: 10.1158/1078-0432.Ccr-04-2653 |
0.581 |
|
| 2005 |
Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular Cell. 18: 13-24. PMID 15808505 DOI: 10.1016/J.Molcel.2005.03.008 |
0.487 |
|
| 2005 |
Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle (Georgetown, Tex.). 4: 540-2. PMID 15753657 DOI: 10.4161/Cc.4.4.1614 |
0.539 |
|
| 2005 |
Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 102: 2703-6. PMID 15659546 DOI: 10.1073/Pnas.0409370102 |
0.495 |
|
| 2004 |
Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathology. 21: 53-6. PMID 15700833 DOI: 10.1007/Bf02484510 |
0.653 |
|
| 2004 |
Schmidt MH, Hoeller D, Yu J, Furnari FB, Cavenee WK, Dikic I, Bögler O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex. Molecular and Cellular Biology. 24: 8981-93. PMID 15456872 DOI: 10.1128/Mcb.24.20.8981-8993.2004 |
0.545 |
|
| 2003 |
Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, ... ... Furnari FB, et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proceedings of the National Academy of Sciences of the United States of America. 100: 13418-23. PMID 14593198 DOI: 10.1073/Pnas.1233632100 |
0.474 |
|
| 2003 |
Schmidt MH, Furnari FB, Cavenee WK, Bögler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proceedings of the National Academy of Sciences of the United States of America. 100: 6505-10. PMID 12734385 DOI: 10.1073/Pnas.1031790100 |
0.574 |
|
| 2002 |
Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Research. 62: 6764-9. PMID 12438278 |
0.617 |
|
| 2002 |
De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. Journal of Neurochemistry. 81: 575-88. PMID 12065666 DOI: 10.1046/J.1471-4159.2002.00847.X |
0.47 |
|
| 2001 |
Klingler-Hoffmann M, Fodero-Tavoletti MT, Mishima K, Narita Y, Cavenee WK, Furnari FB, Huang HJ, Tiganis T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. The Journal of Biological Chemistry. 276: 46313-8. PMID 11514572 DOI: 10.1074/jbc.M106571200 |
0.635 |
|
| 2001 |
Chuenkova MV, Furnari FB, Cavenee WK, Pereira MA. Trypanosoma cruzi trans-sialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. Proceedings of the National Academy of Sciences of the United States of America. 98: 9936-41. PMID 11481434 DOI: 10.1073/pnas.161298398 |
0.539 |
|
| 2001 |
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes & Development. 15: 1311-33. PMID 11390353 DOI: 10.1101/Gad.891601 |
0.512 |
|
| 2001 |
Fan X, Furnari FB, Cavenee WK, Castresana JS. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. International Journal of Oncology. 18: 1023-6. PMID 11295051 |
0.491 |
|
| 2000 |
Bögler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, Cavenee WK. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology. 2: 6-15. PMID 11302255 DOI: 10.1093/Neuonc/2.1.6 |
0.496 |
|
| 2000 |
Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene. 19: 2687-94. PMID 10851068 DOI: 10.1038/sj.onc.1203587 |
0.538 |
|
| 1999 |
Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 18: 3936-43. PMID 10435616 DOI: 10.1038/sj.onc.1202774 |
0.579 |
|
| 1998 |
Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Research. 58: 5002-8. PMID 9823298 |
0.569 |
|
| 1998 |
Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 95: 9418-23. PMID 9689095 DOI: 10.1073/Pnas.95.16.9418 |
0.531 |
|
| 1998 |
Carethers JM, Furnari FB, Zigman AF, Lavine JE, Jones MC, Graham GE, Teebi AS, Huang HJ, Ha HT, Chauhan DP, Chang CL, Cavenee WK, Boland CR. Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome. Cancer Research. 58: 2724-6. PMID 9661881 |
0.469 |
|
| 1997 |
Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proceedings of the National Academy of Sciences of the United States of America. 94: 12479-84. PMID 9356475 DOI: 10.1073/pnas.94.23.12479 |
0.578 |
|
| 1996 |
Furnari FB, Huang HJ, Cavenee WK. Molecular biology of malignant degeneration of astrocytoma. Pediatric Neurosurgery. 24: 41-9. PMID 8817614 |
0.511 |
|
| 1995 |
Furnari FB, Huang HJ, Cavenee WK. Genetics and malignant progression of human brain tumours. Cancer Surveys. 25: 233-75. PMID 8718522 |
0.492 |
|
| 1995 |
Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Research. 55: 1351-4. PMID 7882335 |
0.543 |
|
| 1995 |
Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Research. 55: 1941-5. PMID 7728764 |
0.573 |
|
| Show low-probability matches. |